TAZ促进胃癌中血管生成及相关机制的研究

白婧如 赵秀兰 孙冉 张丹芳 刘铁菊 张艳辉 董学易 车娜 梁晓辉 程润芬 刘爽

白婧如, 赵秀兰, 孙冉, 张丹芳, 刘铁菊, 张艳辉, 董学易, 车娜, 梁晓辉, 程润芬, 刘爽. TAZ促进胃癌中血管生成及相关机制的研究[J]. 中国肿瘤临床, 2019, 46(6): 272-277. doi: 10.3969/j.issn.1000-8179.2019.06.173
引用本文: 白婧如, 赵秀兰, 孙冉, 张丹芳, 刘铁菊, 张艳辉, 董学易, 车娜, 梁晓辉, 程润芬, 刘爽. TAZ促进胃癌中血管生成及相关机制的研究[J]. 中国肿瘤临床, 2019, 46(6): 272-277. doi: 10.3969/j.issn.1000-8179.2019.06.173
Bai Jingru, Zhao Xiulan, Sun Ran, Zhang Danfang, Liu Tieju, Zhang Yanhui, Dong Xueyi, Che Na, Liang Xiaohui, Cheng Runfen, Liu Shuang. TAZ promoting angiogenesis and its mechanism in gastric cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 46(6): 272-277. doi: 10.3969/j.issn.1000-8179.2019.06.173
Citation: Bai Jingru, Zhao Xiulan, Sun Ran, Zhang Danfang, Liu Tieju, Zhang Yanhui, Dong Xueyi, Che Na, Liang Xiaohui, Cheng Runfen, Liu Shuang. TAZ promoting angiogenesis and its mechanism in gastric cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 46(6): 272-277. doi: 10.3969/j.issn.1000-8179.2019.06.173

TAZ促进胃癌中血管生成及相关机制的研究

doi: 10.3969/j.issn.1000-8179.2019.06.173
基金项目: 

国家自然科学基金项目 81572872

详细信息
    作者简介:

    白婧如 专业方向为肿瘤病理学研究。E-mail:bjr240578571@126.com

    通讯作者:

    赵秀兰 xiulanzhao@aliyun.com

TAZ promoting angiogenesis and its mechanism in gastric cancer

Funds: 

the National Natural Science Foundation of China 81572872

More Information
  • 摘要:   目的   探究Hippo通路关键效应分子TAZ在胃癌组织中的表达及其在胃癌血管生成中的作用。  方法   通过免疫组织化学法分析150例胃癌组织标本中TAZ和β-catenin的表达情况;将TAZ过表达质粒及干扰质粒通过慢病毒分别转染至胃癌细胞系MGC803和MKN28中,通过细胞功能实验检测内皮细胞成管、增殖及迁移能力;使用Western blot法检测转染后的胃癌细胞中TAZ及β-catenin的表达情况;采用酶联免疫吸附试验(ELISA)检测TAZ转染后血管内皮生长因子(vascular endothelial growth factor,VEGF)蛋白表达的变化。  结果   免疫组织化学法结果显示150例胃癌组织中,TAZ阳性表达64例(阳性率43%),主要定位于细胞核,其表达与肿瘤分级、TNM分期、转移及微血管密度(microvessel density,MVD)有关(P < 0.05)。此外,在TAZ阳性组中β-catenin阳性表达率为67.2%,明显高于TAZ阴性组,TAZ的表达与β-catenin呈正相关。在MKN28细胞系中上调TAZ的表达,与HUVEC细胞共培养后增强了内皮细胞增殖及管道形成能力,此外还通过促进β-catenin的表达,增强了内皮细胞的迁移能力;相反,在MGC803细胞系中下调TAZ的表达,与HUVEC共培养后减弱了内皮细胞增殖和管道形成能力,此外还通过降低β-catenin的表达,抑制了内皮细胞的迁移能力。  结论  胃癌细胞TAZ的高表达可能通过促进β-catenin和VEGF的表达,进而增强胃癌血管生成能力。

     

  • 图  1  免疫组织化学法检测人胃癌组织中TAZ与β-catenin表达情况(×200)

    A:TAZ阳性表达;B:TAZ阴性表达;C:β-catenin阳性表达;D:β-catenin阴性表达

    图  2  胃癌中TAZ与MVD的关系及生存分析图

    A:高表达TAZ组MVD数量多于低表达TAZ组;B:TAZ阳性患者生存期较TAZ阴性组患者生存期短

    图  3  TAZ对内皮细胞管道形成能力及迁移能力的影响

    A,B:过表达与降表达TAZ对内皮细胞管道能力的影响;C,D:过表达与降表达TAZ对内皮细胞迁移能力的影响;*P<0.05

    图  4  TAZ对内皮细胞增殖能力的影响;*P<0.05

    图  5  免疫荧光与Western blot检测TAZ与β-catenin的表达变化

    A:免疫荧光检测TAZ转染后β-catenin的表达变化;B,C:Western blot法检测TAZ转染后TAZ与β-catenin的表达;*P<0.05

    图  6  ELISA法对各组肿瘤细胞培养基中VEGF因子检测情况;*P<0.05

    表  1  TAZ与β-catenin的相关分析  例

    表  2  TAZ的表达与胃癌临床病理特征的关系  例

  • [1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. doi: 10.3322/caac.v68.6
    [2] Katayama Y, Uchino J, Chihara Y, et al. Tumor Neovascularization and Developments in Therapeutics[J]. Cancers (Basel), 2019, 11(3):E316. doi: 10.3390/cancers11030316
    [3] Schimmel L, Gordon E. The precise molecular signals that control endothelial cell-cell adhesion within the vessel wall[J]. Biochem Soc Trans, 2018, 46(6):1673-1680. doi: 10.1042/BST20180377
    [4] Le Guelte A, Dwyer J, Gavard J. Jumping the barrier: VE-cadherin, VEGF and other angiogenic modifiers in cancer[J]. Biol Cell, 2011, 103(12): 593-605. doi: 10.1042/BC20110069
    [5] Hu XY, Hou PF, Li TT, et al. The roles of Wnt/beta-catenin signaling pathway related lncRNAs in cancer[J]. Int J Biol Sci, 2018, (14):2003- 2011.
    [6] Ma R, Feng N, Yu X, et al. Promoter methylation of Wnt/beta-Catenin signal inhibitor TMEM88 is associated with unfavorable prognosis of non-small cell lung cancer[J]. Cancer Biol Med, 2017, 14(4):377-386. doi: 10.20892/j.issn.2095-3941.2017.0061
    [7] Ahmed RA, Shebl AM, Habashy HO. Expression levels of beta-catenin and galectin-3 in meningioma and their effect on brain invasion and recurrence: a tissue microarray study[J]. Cancer Biol Med, 2017, 14(3): 319-326. doi: 10.20892/j.issn.2095-3941.2017.0024
    [8] Clifford RL, Deacon K, Knox AJ. Novel regulation of vascular endothelial growth factor-A (VEGF-A) by transforming growth factor (beta)1: requirement for Smads, (beta)-CATENIN, AND GSK3(beta)[J]. J Biol Chem, 2008, 283(51):35337-35353. doi: 10.1074/jbc.M803342200
    [9] Dilek FH, Topak N, Tokyol C, et al. Beta-Catenin and its relation to VEGF and cyclin D1 expression in pT3 rectosigmoid cancers[J]. Turk J Gastroenterol, 2010, 21(4):365-371. doi: 10.4318/tjg.2010
    [10] Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the Roots of Cancer [J]. Cancer cell, 2016, 29(6):783-803. doi: 10.1016/j.ccell.2016.05.005
    [11] Collak FK, Demir U, Ozkanli S, et al. Increased expression of YAP1 in prostate cancer correlates with extraprostatic extension[J]. Cancer Biol Med, 2017, 14(4):405-413. doi: 10.20892/j.issn.2095-3941.2017.0083
    [12] Park JH, Shin JE, Park HW. The role of hippo pathway in cancer stem cell biology[J]. Mol Cells, 2018, 41(2):83-92. http://cn.bing.com/academic/profile?id=8116c6ce9e1add67fea33a328108c638&encoded=0&v=paper_preview&mkt=zh-cn
    [13] Wang X, Freire Valls A, Schermann G, et al. YAP/TAZ orchestrate VEGF signaling during developmental angiogenesis[J]. Dev Cell, 2017, 42(5): 462-478 e7. doi: 10.1016/j.devcel.2017.08.002
    [14] Cho H, Kim J, Ahn JH, et al. YAP and TAZ negatively regulate prox1 during developmental and pathologic lymphangiogenesis[J]. Circ Res, 2019, 124(2):225-242. doi: 10.1161/CIRCRESAHA.118.313707
    [15] Chan SW, Lim CJ, Guo K, et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells[J]. Cancer Res, 2008, 68(8):2592- 2598. doi: 10.1158/0008-5472.CAN-07-2696
    [16] Wang C, Gu C, Jeong KJ, et al. YAP/TAZ-mediated upregulation of gab2 leads to increased sensitivity to growth factor-induced activation of the PI3K pathway[J]. Cancer Res, 2017, 77(7):1637-1648. doi: 10.1158/0008-5472.CAN-15-3084
    [17] Wang Y, Han Y, Guo Z, et al. Nuclear TAZ activity distinctly associates with subtypes of non-small cell lung cancer[J]. Biochem Biophys Res Commun, 2019, 509(3):828-832. doi: 10.1016/j.bbrc.2019.01.012
    [18] Choi HJ, Zhang H, Park H, et al. Yes-associated protein regulates endothelial cell contact-mediated expression of angiopoietin-2[J]. Nat Commun, 2015, 6:6943. doi: 10.1038/ncomms7943
    [19] Neto F, Klaus-Bergmann A, Ong YT, et al. YAP and TAZ regulate adherens junction dynamics and endothelial cell distribution during vascular development[J]. Elife, 2018, (7):e31037. https://www.ncbi.nlm.nih.gov/pubmed/29400648
    [20] Hwang JH, Kim AR, Kim KM, et al. TAZ couples Hippo/Wnt signalling and insulin sensitivity through Irs1 expression[J]. Nat Commun, 2019, 10 (1):421. doi: 10.1038/s41467-019-08287-x
    [21] Imajo M, Miyatake K, Iimura A, et al. A molecular mechanism that links Hippo signalling to the inhibition of Wnt/beta-catenin signalling[J]. EMBO J, 2012, 31(5):1109-1122. doi: 10.1038/emboj.2011.487
    [22] Xing Y, Zhang Y, Jia L, et al. Lipopolysaccharide from Escherichia coli stimulates osteogenic differentiation of human periodontal ligament stem cells through Wnt/beta-catenin-induced TAZ elevation[J]. Mol Oral Microbiol, 2019, 34(1):1-13.
    [23] Karaman S, Leppanen VM, et al. Vascular endothelial growth factor signaling in development and disease[J]. Development, 2018, 145(14:): 1-8. http://d.old.wanfangdata.com.cn/OAPaper/oai_pubmedcentral.nih.gov_3286203
  • 加载中
图(6) / 表(2)
计量
  • 文章访问数:  68
  • HTML全文浏览量:  2
  • PDF下载量:  4
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-02-15
  • 修回日期:  2019-03-20
  • 刊出日期:  2019-03-30

目录

    /

    返回文章
    返回